Premium
Gene Expression Profiling of Glycosaminoglycan Drived from G. bimaculatus in High Fat Dieted Rat
Author(s) -
Ahn Mi Young,
Hwang Jae Sam,
Yun Eun Young
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.lb152
Subject(s) - endocrinology , medicine , chemistry , glycosaminoglycan , gryllus bimaculatus , hyperlipidemia , lipoprotein lipase , biochemistry , biology , enzyme , diabetes mellitus , ecology , cricket
The glycosaminoglycan (GAG) from cricket (Gryllus bimaculatus) was studied as a potential health supplement. Antiatherosclerotic and antilipemic effects of the GAG (5 or 10 mg/kg) of G. bimaculatus (Gb) were investigated in 15 mo.‐aged Wistar rats treated with glycosaminoglycan for over a month. This GAG of Gb produced meaningful anti‐edema effect showing inhibition of C‐reactive protein (CRP). Also, the weight of abdominal and epididymidal fat was reduced in conjunction with a mild increase in body weight in the rats for over 1‐month. Furthermore, the sero‐biochemical parameters showing anti‐hyperlipdemia effect decreased the levels of Phospholipid, AST, ALT, total cholesterol, and glucose in dose dependent manner. In addition to plasma study, anticoagulant and antithrombotic effects in the GbGAG high fat Wistar rats, platelet, thrombin time, prothrombin time, and Factor I were more increased than control group or Statin (positive) group. Based on these results, GbGAG was shown to prevent or treat fatty liver or hyperlipidemia in high‐fat dieted rats. Furthermore, the GAG treated rat group (10 mg/kg) compared to control, showed that 588 genes (test/control ratio>2.0) including lipocalin 2 (Lcn2), alpha 2‐macroglobulin (A2m) and RT1 class Ib, and locus EC2 (RT1‐EC2) were up‐regulated; and 569 genes (test/control ratio>0.5) including stearoyl‐Coenzyme A desaturase 1 (Scd1), potassium intermediate/small conductance calcium‐activated channel, subfamily N, member 2 (Kcnn2) and ATPase, H+ transporting and lysosomal accessory protein 2 (Atp6ap2) were down‐regulated. Data suggest Lcn2 and A2m related ant‐high fat, were up‐regulated by GbGAG treatment which was indicated to be potential therapeutic markers for anti‐high fat disease.